SML1394
Olmesartan
≥98% (HPLC), Angiotensin II Type I receptor blocker, powder
동의어(들):
4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid, Olmesartan acid
조직 및 계약 가격을 보려면 로그인를 클릭합니다.
크기 선택
제품정보 (DICE 배송 시 비용 별도)
실험식(Hill 표기법):
C24H26N6O3
CAS 번호:
Molecular Weight:
446.50
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
제품 이름
Olmesartan, ≥98% (HPLC)
SMILES string
OC(C)(C)C1=C(C(O)=O)N(CC2=CC=C(C3=C(C4=NNN=N4)C=CC=C3)C=C2)C(CCC)=N1
InChI
1S/C24H26N6O3/c1-4-7-19-25-21(24(2,3)33)20(23(31)32)30(19)14-15-10-12-16(13-11-15)17-8-5-6-9-18(17)22-26-28-29-27-22/h5-6,8-13,33H,4,7,14H2,1-3H3,(H,31,32)(H,26,27,28,29)
InChI key
VTRAEEWXHOVJFV-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 20 mg/mL, clear
storage temp.
2-8°C
Quality Level
Gene Information
human ... AGTR1(185)
관련 카테고리
Application
Olmesartan has been used as an angiotensin II receptor 1 (AT1) receptor inhibitor to study the effect of angiotensin II type 1 receptor interactions in the regulation of renal afferent arterioles in angiotensin II-dependent hypertension.
Biochem/physiol Actions
Olmesartan is an Angiotensin II Type I receptor blocker.
Olmesartan is an Angiotensin II Type I receptor blocker. Olmesartan is the active form of the antihypertensive drug olmesartan medoxomil.
Olmesartan possesses anti-inflammatory and anti-oxidative stress properties. It protects neuronal cells against oligomerized amyloid β (Aβ)-induced cellular senescence.
저장 등급
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Bapi Gorain et al.
Regulatory toxicology and pharmacology : RTP, 82, 20-31 (2016-11-07)
Poor aqueous solubility and unfavourable de-esterification of olmesartan medoxomil (a selective angiotensin II receptor blocker), results in low oral bioavailability of less than 26%. Improvement of oral bioavailability with prolonged pharmacodynamics activity of olmesartan in Wistar rats had been approached
Mi-Yeon Yu et al.
PloS one, 13(8), e0202676-e0202676 (2018-08-28)
Albuminuria is a predictor of disease progression in patients with chronic kidney disease (CKD). However, the ability of proteinuria parameters measured at various time periods to predict renal outcomes is unclear. This observational cohort study included 165 non-diabetic hypertensive CKD
C Custodero et al.
Ageing research reviews, 46, 42-59 (2018-05-29)
Growing evidence suggests chronic low-grade inflammation (LGI) as a possible mechanism underlying the aging process. Some biological and pharmaceutical compounds may reduce systemic inflammation and potentially avert functional decline occurring with aging. The aim of the present meta-analysis was to
Elham Bakhtiari et al.
Toxicology mechanisms and methods, 25(8), 614-621 (2015-09-04)
Over expression of renin-angiotensin system (RAS) and nuclear factor-kappaB (NF-κB) has a major role in many cancers. It has been suggested that some angiotensin receptor blockers (ARBs) could reduce the proliferation of cancer cells. The role of NF-κB pathway has
Nanako Muraya et al.
Oxidative medicine and cellular longevity, 2018, 7635274-7635274 (2018-07-04)
Oxidative stress induced by hyperuricemia is closely associated with the renin-angiotensin system, as well as the onset and progression of cardiovascular disease (CVD) and chronic kidney disease (CKD). It is therefore important to reduce oxidative stress to treat hyperuricemia. We
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.